{
    "2018-08-29": [
        [
            {
                "time": "2018-06-30",
                "original_text": "复星国际上半年净利润68.6亿元 健康板块利润增长31.2%",
                "features": {
                    "keywords": [
                        "复星国际",
                        "净利润",
                        "健康板块",
                        "利润增长"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "金融",
                        "健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-29",
                "original_text": "【盘前看市】等待缩量回调机会 低吸超跌白马股和科技股",
                "features": {
                    "keywords": [
                        "盘前看市",
                        "缩量回调",
                        "白马股",
                        "科技股"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技",
                        "消费"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-06-30",
                "original_text": "复星医药2018年上半年营收、研发投入双增长，海外布局效应明显",
                "features": {
                    "keywords": [
                        "复星医药",
                        "营收增长",
                        "研发投入",
                        "海外布局"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-29",
                "original_text": "持仓全貌曝光 基金继续青睐消费股",
                "features": {
                    "keywords": [
                        "基金",
                        "消费股",
                        "持仓"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "消费"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-29",
                "original_text": "8月29日券商晨会研报汇编",
                "features": {
                    "keywords": [
                        "券商晨会",
                        "研报汇编"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-08-29",
                "original_text": "【医药-崔文亮】复星医药：非经常性投资收益下滑及费用率上升拖累公司业绩，研发迎来收获期 盈利能力下降",
                "features": {
                    "keywords": [
                        "复星医药",
                        "投资收益下滑",
                        "费用率上升",
                        "盈利能力下降",
                        "研发收获期"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}